目的 觀察西黃丸聯(lián)合紫杉醇注射液聯(lián)合注射用順鉑（TP方案）治療中晚期乳腺癌的臨床療效。方法 收集開封市中心醫(yī)院2014年1月-2016年2月確診的中晚期乳腺癌患者123例為研究對象，根據(jù)抗腫瘤方案分為對照組（59例）和治療組（64例）。對照組接受TP方案治療：第1天靜脈滴注紫杉醇注射液，150 mg/m²，1次/d；第2~4天靜脈滴注注射用順鉑，25 mg/m²，1次/d。3周為1個化療周期，共完成4個化療周期。治療組在對照組治療的基礎(chǔ)上口服西黃丸，3 g/次，2次/d，連續(xù)使用12周。評價兩組患者臨床療效，同時比較治療前后生活質(zhì)量評分、血清腫瘤標志物水平、毒性反應(yīng)和1、2年生存情況。結(jié)果 治療后，對照組、治療組客觀緩解率分別為40.7%、75.0%，疾病控制率分別為74.6%、87.5%，兩組臨床療效比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者KPS評分、FACT-B評分均顯著升高，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組患者生活質(zhì)量評分明顯高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，治療組癌胚抗原（CEA）、糖類抗原125（CA125）、糖類抗原153（CA153）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組血清腫瘤標志物水平明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療期間兩組均有化療毒性反應(yīng)出現(xiàn)，治療組毒性反應(yīng)發(fā)生率低于對照組，但差異不具有統(tǒng)計學意義。治療組1年生存率、2年生存率明顯高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 西黃丸聯(lián)合TP方案治療中晚期乳腺癌具有較好的療效，改善生活質(zhì)量，降低血清腫瘤標志物水平，安全性好，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the effects of Xihuang Pills combined with TP regimen in treatment of middle and advanced breast cancer. Methods Patients (123 cases) with breast cancer in Kaifeng City Center Hospital from January 2014 to February 2016 were divided into control (59 cases) and treatment group (64 cases) according to the anti-tumor scheme. Patients in the control group were given TP regimen, and patients were iv administered with Paclitaxel Injection 150 mg/m², once daily, and were iv administered with Cisplatin for injection (25 mg/m²) at the second to fourth day. Three weeks was a chemotherapy cycle, and four chemotherapy cycles were completed. Patients in the treatment group were po administered with Xihuang Pills on the basis of the control group, 3 g/time, twice daily, and were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and quality of life score, serum levels of tumor marker, toxic reaction, and survival rate in two groups were compared. Results After treatment, the objective remission rates in the control and treatment groups were 40.7% and 75.0%, respectively, and disease control rates in the control and treatment groups were 74.6% and 87.5%, respectively, and there was difference between two groups (P<0.05). After treatment, KPS scores and FACT-B scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the quality of life scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CEA, CA125, and CA153 in two groups were significantly decreased, and the difference was significant in the same group (P<0.05). And the serum levels of tumor markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Chemotoxicity was observed in both groups during the treatment period. The incidence of toxic reaction in the treatment group was lower than that in the control group, but there was not statistically significant difference. The one-year survival rate and two-year survival rate in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xihuang Pills combined with TP regimen has clinical curative effect in treatment of middle and advanced breast cancer, can improve the quality of life, reduce the levels of tumor markers, with good safety, which has a certain clinical application value.